Welcome to our dedicated page for Nanovibronix news (Ticker: NAOV), a resource for investors and traders seeking the latest updates and insights on Nanovibronix stock.
This page provides a historical news feed for NanoVibronix, Inc. under the ticker NAOV, which later changed its corporate name to ENvue Medical, Inc. and its Nasdaq ticker to FEED. The archived coverage reflects the company’s evolution as a medical technology business focused on non-invasive therapeutic systems and minimally invasive navigation platforms for enteral care and related clinical applications.
News items associated with NAOV include announcements about the company’s acoustic-based therapeutic technologies, such as PainShield and UroShield, which use proprietary low-intensity surface acoustic wave technology and are intended to treat pain, reduce bacterial colonization, and disrupt biofilms in home or care settings. Releases also describe developments around the UroShield Kit, including its addition to the UK National Health Service Drug Tariff Part IX and the resulting prescription reimbursement pathway across the UK.
Another major theme in the NAOV news history is the integration and expansion of the ENvue Navigation Platform, a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. Company communications highlight FDA 510(k) clearance for adult use, real-time bedside visualization of tube movement, and plans to build a broader enteral-feeding ecosystem around this platform. Additional stories cover training initiatives, such as the Oscar training aid for naso-enteral feeding procedures, and intellectual property developments related to navigation technology.
Investors and observers can use this NAOV news archive to trace key milestones such as the strategic shift toward enteral navigation, financing transactions disclosed in press releases, and the formal rebranding to ENvue Medical, Inc. For the most recent developments after the name and ticker change, subsequent news is released under the FEED symbol.
NanoVibronix, Inc (NASDAQ: NAOV) released a shareholder letter detailing the company's performance in 2022 and its prospects for 2023. Despite challenges, including regulatory delays that caused a revenue drop of approximately $900,000, the company has made strategic advancements, such as transitioning to a more effective distributor and reintroducing PainShield Plus. Positive clinical evaluations highlight the effectiveness of UroShield, showing improved patient outcomes and satisfaction. The company is focused on increasing distribution, particularly in VA hospitals, and expanding its international presence. Financially, the company ended 2022 with $2.7 million in cash and invested $2.4 million in inventory to support future sales. NanoVibronix emphasizes a strong potential for growth in 2023, with ongoing product studies and new contracts expected to drive revenue.
NanoVibronix, Inc. (NASDAQ: NAOV) announced successful independent life expectancy testing for its PainShield device, affirming that it met all functionalities required. The testing, conducted by Carmel Labs in Israel, confirms the device’s reliability. CEO Brian Murphy indicated that the results will support their pending application for Medicare coverage, following a prior denial in September 2022 due to insufficient data. This advancement is expected to enhance the product's market availability and potential reimbursement opportunities.
NanoVibronix, Inc. (NASDAQ: NAOV) has filed a provisional patent application for its enhanced UroShield device, titled "Multiple Frequency Surface Acoustic Waves for Internal Medical Device." The newly developed UroShield Ultra aims to improve catheter coupling and reduce bacterial infections with multiple actuators operating at various frequencies. CEO Brian Murphy emphasized its role in preventing Catheter Associated Urinary Tract Infections (CAUTI), a leading source of hospital-acquired infections. This innovation strengthens NanoVibronix's intellectual property portfolio and its position in the medical device market.
NanoVibronix, Inc. (NASDAQ: NAOV) announced positive evaluation results for its UroShield device at a recent medical conference. The report, conducted by clinicians from the Royal National Orthopaedic Hospital, indicates a decrease in blockages and infections, as well as increased patient satisfaction with catheters. The device is believed to improve quality of life and reduce healthcare costs for patients with spinal cord injuries. CEO Brian Murphy emphasized the significant market opportunity, as approximately 285,000 individuals in the U.S. and 50,000 in the UK live with such injuries.
FAQ
What is the current stock price of Nanovibronix (NAOV)?
What is the market cap of Nanovibronix (NAOV)?
